Wet Age-Related Macular Degeneration Market Share Analysis of the Top Industry Players, Growth Opportunities - P&S Intelligence

The market is predominantly driven by the increase in prevalence of AMD, lack of availability of specific treatment, and surge in geriatric population, according to P&S Intelligence.Lucentis, Eylea, and Avastin are the key drugs available globally for the management of wet AMD. Among these, Eylea is expected to dominate the market during the forecast period. Increasing prevalence of AMD and rise in demand for Eylea are some of the major factors propelling the demand for this drug in the wet age-related macular degeneration market.

Based on the route of administration, the wet age-related macular degeneration market is bifurcated into intravitreally and intravenously administered drugs. During the forecast period, the market is expected to witness faster growth in the category of drugs administered through the intravitreal route, with 7.2% CAGR.

Access Detailed Report Summary: https://www.psmarketresearch.com/market-analysis/wet-age-related-macular-degeneration-market

Geographically, North America holds the largest share in the wet age-related macular degeneration market, with an estimated revenue contribution of around $3.0 billion in 2018. Rising prevalence of wet AMD, growing number of drug approvals, and extensive presence of key players in the region are the key factors supporting the market growth in North America.

Request to Get the Sample Pages at: https://www.psmarketresearch.com/market-analysis/wet-age-related-macular-degeneration-market/report-sample

Also, since the treatment of wet AMD is quite expensive, government in countries, such as South Korea and Malaysia, have introduced health insurance plans that cover some of the treatment cost to reduce the healthcare burden on people. For instance, under South Korea’s universal government health insurance plan, patients suffering from wet AMD can receive up to 10 injections of ranibizumab during their lifetime. Thus, government initiatives in the form of medical reimbursements are supporting the growth of the wet age-related macular degeneration market in the APAC region.

Make Enquiry Before Buying the Report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=wet-age-related-macular-degeneration-market

Additionally, in February 2019, Ocular Therapeutix Inc. administered the first dose of OTX-TKI (tyrosine kinase inhibitor implant) to the first patient in the phase I trial to evaluate the efficacy of the drug in patients with wet AMD. The phase I trial is a multi-center, open-label study to test the safety, durability, and tolerability of OTX-TKI.

The global wet age-related macular degeneration market is marked by the presence of several large players, such as Regeneron Pharmaceuticals Inc., Neurotech Pharmaceuticals Inc., Ophthotech Corporation, Kubota Pharmaceutical Holdings Co. Ltd., Gilead Sciences Inc., Novartis AG, Alimera Sciences Inc., and Bayer AG.

About P&S Intelligence
P&S Intelligence is a provider of market research and consulting services catering to the market information needs of burgeoning industries across the world. Providing the plinth of market intelligence, P&S as an enterprising research and consulting company, believes in providing thorough landscape analyses on the ever-changing market scenario, to empower companies to make informed decisions and base their business strategies with astuteness.

Contact:
P&S Intelligence
Toll-free: +1-888-778-7886 (USA/Canada)
International: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com

This release was published on openPR.